Patents Issued in February 16, 2017
  • Publication number: 20170042929
    Abstract: The present invention is directed to novel treatment of controlling hippocampal neural circuit hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comprising the step of contacting the hippocampus in said subject with a compound effective to restore excitatory/inhibitor balance thereby controlling the neural circuit hyperexcitability. Further provided is a method of treating a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comprising the step of administering an amount of an adenosine A1 receptor agonist pharmacologically effective to block epileptogenetic activities without blocking excitatory synaptic transmission.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 16, 2017
    Inventors: Jokubas Ziburkus, Jason Eriksen, Feng Gu
  • Publication number: 20170042930
    Abstract: Provided is a method of enhancing toxicity of a glycolytic dependent compound towards a cell, tissue and/or organ e.g. a diseased cell, tissue and/or organ, the method comprises contacting Oxidized Regenerated Cellulose (ORC) and/or Oxidized Cellulose (OC); and a glycolytic dependent compound with the cell, tissue and/or organ. The ORC and/or OC; and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.
    Type: Application
    Filed: August 11, 2016
    Publication date: February 16, 2017
    Inventor: James Galloway
  • Publication number: 20170042931
    Abstract: Methods for targeting microRNA 128 (miR-128) for regulating cholesterol/lipid metabolism and insulin sensitivity.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 16, 2017
    Inventors: Anders M. Naar, Seyed Hani Najafi-Shoushtari
  • Publication number: 20170042932
    Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
    Type: Application
    Filed: October 7, 2016
    Publication date: February 16, 2017
    Inventors: Bernardus Nicolaas Machielse, Allan Darling
  • Publication number: 20170042933
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • Publication number: 20170042934
    Abstract: Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.
    Type: Application
    Filed: February 13, 2015
    Publication date: February 16, 2017
    Inventors: Carlos Andre Passos Bastos, Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria, Bradley Michael VIS
  • Publication number: 20170042935
    Abstract: An object of the present invention is to provide magnesium oxide that can be preferably used for pharmaceutical applications or as a food additive. In particular, the object is to provide magnesium oxide granules with which tableting problems and quality defects can be reduced, and in more particular, to provide magnesium oxide granules with which tableting problems and quality defects can be reduced and which has less heavy metal incorporation and high purity of magnesium oxide. Provided are magnesium oxide granules for pharmaceutical applications or for addition to food having a BET specific surface area of 7 to 50 m2/g and CAA80/CAA40 of 2 to 7.
    Type: Application
    Filed: February 25, 2014
    Publication date: February 16, 2017
    Applicant: KONOSHIMA CHEMICAL CO., LTD.
    Inventor: Kensho SAKAMOTO
  • Publication number: 20170042936
    Abstract: The present disclosure relates to a composition for treatment and/or prevention of infections, namely bone diseases, in particular osteomyelitis, via a controlled release of antibiotics and subsequently induce regeneration of bone tissue that often undergoes necrosis due to infection. The present disclosure relates in particular to a pharmaceutical composition comprising one or more granules containing calcium phosphate, collagen and one or more polymers of heparin, and an antibiotic in an effective therapeutic amount, wherein the antibiotic is bound to the heparin polymers.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 16, 2017
    Inventors: Fernando Jorge MONTEIRO, Susana Maria RIBEIRO E SOUSA MENDES DE FREITAS, Catarina COELHO, Nuno Paulo ALEGRETE DA SILVA
  • Publication number: 20170042937
    Abstract: The present invention provides a deep sea water extract and a method for inhibiting the proliferation of Helicobacter pylori strains using the deep sea water extract, wherein the deep sea water extract has an organic component with a molecular weight of 685 to 690, 733 to 738 and 1,070 to 1,075. The deep sea water extract of the present invention can be applied in the prevention and treatment of H pylori infection.
    Type: Application
    Filed: April 14, 2016
    Publication date: February 16, 2017
    Inventors: Chiang-Ting Chien, Jyh-Chin Yang, Ping-Yi Huang, Cheng-Huang Lin, Kwun-min Chen
  • Publication number: 20170042938
    Abstract: The present invention relates to the use of a photoactivatable Porphyrin-Derivative in extracorporeal photophoresis (ECP) treatment, in which a patient's blood of part of it containing said Porphyrin-derivative is/are exposed to light of a wavelength which activates said photoactivatable Porphyrin-Derivative.
    Type: Application
    Filed: April 24, 2015
    Publication date: February 16, 2017
    Inventor: Qian Peng
  • Publication number: 20170042939
    Abstract: The disclosure discloses a kind of new NKT-like cell subpopulation, a therapeutical composition comprising the NKT-like cell subpopulation, and the medical use thereof. The disclosure also provides a preparation method of the NKT-like cell subpopulation. The disclosed NKT-like cell subpopulation has a strong antitumor effect, and can be adoptive transferred into a subject to treat the tumor in the subject after in vitro cultured and amplified.
    Type: Application
    Filed: August 8, 2016
    Publication date: February 16, 2017
    Applicant: Tsinghua University
    Inventor: Minghui ZHANG
  • Publication number: 20170042940
    Abstract: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin.
    Type: Application
    Filed: October 6, 2016
    Publication date: February 16, 2017
    Inventors: Xavier Stephenne, Etienne Sokal, Mustapha Najimi, Stéphane Eeckhoudt, Cédric Hermans
  • Publication number: 20170042941
    Abstract: The present invention refers to a method of obtaining a composition comprising a cell suspension comprising hair progenitor cells (HPCs) from a human subject and plasma derived growth factors, which comprises the following steps: a. Incubating an isolated tissue sample comprising at least one complete hair follicle from the subject, preferably from the occipital region of the head of the subject, in a suspension of plasma derived growth factors, preferably obtained from the subject; for a period of time between 15 minutes and 1 hour at a temperature of approximately 37° C.; and b. Removing the tissue fragments from the product of step a); preferably by filtration; wherein in this method the cells from the tissue obtained from the sample of step a) are not enzymatically digested. The present invention also refers to a cell suspension or composition produced by the method thereof as well as the uses of such composition or cell suspension.
    Type: Application
    Filed: April 24, 2015
    Publication date: February 16, 2017
    Inventor: Alberto Gorrochategui Barrueta
  • Publication number: 20170042942
    Abstract: The present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a CTLA4 peptide-immunoglobulin fusion, preferably LEA29Y, and expresses said CTLA4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Eckhard WOLF, Nikolai KLYMIUK, Lelia WOLF-VAN BUERCK, Jochen SEIßLER
  • Publication number: 20170042943
    Abstract: A transplant product made from human amniotic fluid has a supernatant from filtered and centrifuged amniotic fluid, the amniotic fluid when recovered aseptically having a clear, translucent to slightly pink or tan color. The supernatant had been taken from the amniotic fluid which had been passed through a 170 to 260 micron blood filter, then centrifuged for 5 minutes or more at 400 g and thereafter the supernatant was separated from a pellet of debris, leaving the biochemical properties intact, wherein the supernatant is cryofrozen in sized cryovials having 0.25 to 2.0 ml of the supernatant at a temperature of ?65 degrees or less prior to use and the transplant products method of use. The transplant product contains cellular material, cell fragments, proteins and growth factors maintaining the biochemical properties and is non-immunogenic while having particles up to 170 microns being passable through a 30 gauge syringe for injection.
    Type: Application
    Filed: August 11, 2015
    Publication date: February 16, 2017
    Applicant: VIVEX BIOMEDICAL, INC.
    Inventors: Shabnam Namin, Gaëtan Jean-Robert Delcroix
  • Publication number: 20170042944
    Abstract: Provided herein are compositions and methods for treating one or more disorders or conditions in infants, including premature infants, by administering to such infants umbilical cord blood or cells obtained from umbilical cord blood and, optionally, cells obtained from placental perfusate, placental stem cells and/or blood additives. Also provided herein are methods for treating one or more disorders or conditions in infants, including premature infants, by administering to such infants cells obtained from placental perfusate alone or placental stem cells alone or in combination with umbilical cord blood or cells obtained from umbilical cord blood.
    Type: Application
    Filed: April 20, 2015
    Publication date: February 16, 2017
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. HARIRI, Jodi P. GURNEY, Xiaokui ZHANG, Stacy Herb, Cindy HARTUNG
  • Publication number: 20170042945
    Abstract: The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Applicant: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan
  • Publication number: 20170042946
    Abstract: The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, Homarus americanus in particular.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventor: Robert C. Bayer
  • Publication number: 20170042947
    Abstract: The present invention provides an unsaturated fatty acid absorption accelerator comprising a wax as an active ingredient. The absorption of unsaturated fatty acids can be accelerated by using the absorption accelerator of the present invention.
    Type: Application
    Filed: March 30, 2015
    Publication date: February 16, 2017
    Applicant: Yamada Bee Company, Inc.
    Inventors: Nakamichi WATANABE, Tetuya SADO, Hiromi NAKATUKA, Takayuki KONO
  • Publication number: 20170042948
    Abstract: Disclosed herein are compositions that have substantially purified Christensenellaceae bacteria, and uses of these compositions to alter the microbiome of an individual. The addition of Christensenellaceae bacteria, such as Christensenella, to the microbiome of an individual can treat or prevent weight gain, reduce body weight, inhibit fat accumulation, reduce excess adiposity, and reduce a high body mass index (BMI), and can also treat or prevent conditions correlating with excess weight and fat and a high BMI, such as insulin sensitivity, metabolic syndrome, excess adiposity, and diabetes.
    Type: Application
    Filed: April 23, 2015
    Publication date: February 16, 2017
    Applicant: CORNELL UNIVERSITY
    Inventors: Ruth E. LEY, Julia GOODRICH, Jillian WATERS
  • Publication number: 20170042949
    Abstract: Provided are shelf-stable probiotic compositions comprising endospores of Bacillus with desirable characteristics such as acid resistance, high temperature tolerance, and high levels of phytase, ?-amylase, cellulolytic and/or protease enzyme activities. Methods for their use, e.g. in food for animal and human consumption, are also provided, as are food products which comprise the probiotics and methods of making the same.
    Type: Application
    Filed: April 15, 2015
    Publication date: February 16, 2017
    Inventors: ALEJANDRO PENALOZA-VAZQUEZ, PATRICIA RAYAS-DUARTE
  • Publication number: 20170042950
    Abstract: Described herein is a composition comprising a mixture of a probiotic composition and a prebiotic composition, wherein the probiotic composition comprises the bacterium Bacillus coagulans and wherein the prebiotic composition comprises a plant-based fiber, a resistant starch and a short-chain oligosaccharide. Uses of the compositions described herein for maintaining or improving gastrointestinal health is also contemplated.
    Type: Application
    Filed: August 10, 2016
    Publication date: February 16, 2017
    Inventors: Francis C. Lau, Bruce P. Daggy, Emanuel P. Fakoukakis
  • Publication number: 20170042951
    Abstract: A composition for human and animal use as a therapy for the treatment of tumors, acquired immunodeficiency syndrome and leukemias is described. The composition, for human and animal use as an antitumor agent has a strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (Th1) interferon INF-gamma, the cytokines exhibiting a marked antitumor activity, and/or a strain of bacteria Lactobacillus salivarius LS06 DSM 26037 which is able to strongly stimulate the production of dendritic cells, the dendritic cells also exhibiting a marked antitumor activity.
    Type: Application
    Filed: April 30, 2015
    Publication date: February 16, 2017
    Inventor: Giovanni MOGNA
  • Publication number: 20170042952
    Abstract: Process for removing pesticides from Ginkgo biloba extracts, which involves submitting an extract obtained by conventional methods to the following steps: a. Liquid-liquid extraction of the extract to obtain a medium polarity fraction containing ginkgo terpenes and pesticides not removable with hexane, and a high polarity fraction containing ginkgo flavone glycosides; b. crystallisation from the medium polarity fraction obtained at step a) to give an intermediate with a ginkgolide content of not less than 50%; c. crystallisation from the residual solution obtained at step b) to give an intermediate with a bilobalide content of not less than 50%; d. mixing of the high polarity fraction obtained at step a) with the ginkgo terpene intermediate and the bilobalide intermediate obtained at steps b) and c).
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Applicant: Indena S.P.A.
    Inventors: Andrea Giori, Giacomo Mombelli, Sabrina Arpini, Mario Acerbi
  • Publication number: 20170042953
    Abstract: A nutritional supplement composition is formulated for oral administration and enhances cognitive function. It includes huperzine A, Ginkgo biloba, and acetyl-L-carnitine. The huperzine A, acetyl-L-carnitine, and Ginkgo biloba together account for at least 80 wt % of a dosage unit of the composition. The Ginkgo biloba is about 5.0% to about 12.0%, by weight of the huperzine A, acetyl-L-carnitine and Ginkgo biloba. The Ginkgo biloba and acetyl-L-carnitine are in a ratio of y:z respectively, wherein y is between about 690 and 1,030 for Ginkgo biloba and z is between about 8,000 and 12,000 for acetyl-L-carnitine.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventor: Josh REYNOLDS
  • Publication number: 20170042954
    Abstract: A nutritional supplement composition for enhancing cognitive function includes Ginkgo biloba, rhodiola, acetyl-L-carnitine and huperzine A. The Ginkgo biloba, rhodiola and acetyl-L-carnitine are in a ratio a:b:c respectively such that a as the Ginkgo biloba is between about 690 and 1030, b as the rhodiola is between about 1,700 and 2,600 and c as the acetyl-L-carnitine is between about 8,000 and 12,000. The composition is formulated for oral administration and the Ginkgo biloba, rhodiola, acetyl-L-carnitine and huperzine A together account for at least 80 wt % of a dosage unit of the nutritional supplement composition.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventor: Josh REYNOLDS
  • Publication number: 20170042955
    Abstract: The present invention discloses novel antifungal herbal composition comprising standardized ethyl acetate extracts or active ingredients isolated from ethyl acetate extract of Lawsonia inermis, for the management of fungal infections, including those caused by (Candida sp., Cryptococcosis sp., Aspergillus sp., Penicillium sp, Tinea sp and Blastomyces sp.). More particularly, the present invention discloses herbal composition comprising ethyl acetate extracts of Lawsonia inermis or the compositions comprising at least one of active ingredients selected from Lawsone & lawsoniaside and luteoline, for the management of fungal infections.
    Type: Application
    Filed: April 23, 2015
    Publication date: February 16, 2017
    Inventor: Vivek Anand Parachur
  • Publication number: 20170042956
    Abstract: The present invention deals with an Embelia extract—preferably an extract from Embelia concinna titrated in flavonoids—, its process for preparation and its use in a cosmetical or pharmaceutical composition for the treatment of skin sensitivity, for the treatment of allergic reactions of the skin, for soothing and for the treatment of itching skin and for the regulation of inflammatory drifts in the skin
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Inventors: VIRGINIE PETIT, ERIC THERON
  • Publication number: 20170042957
    Abstract: The invention relates to a Mangifera (Mango) Indica preparation as Sirtuin 1 activating agent for in vivo and in vitro applications. The preparation may be used to reduce the risk of developing obesity, type II diabetes, elevated blood lipid levels, artheriosclerosis and cardiovascular diseases, as well as a cell and DNA protector.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 16, 2017
    Inventors: Sybille Buchwald-Werner, Karin Berger Buter
  • Publication number: 20170042958
    Abstract: A composition for applying to skin in need of treatment for skin barrier restoration, hydration and moisturization, the composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin. Also provided are methods for treating skin in need of skin barrier treatment, methods of treating skin to reduce the signs of aging and methods of treating skin to reduce the signs of inflammation with a composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin.
    Type: Application
    Filed: September 24, 2015
    Publication date: February 16, 2017
    Inventors: Hua Du, Yan Li, Tao Liu, Yingxin Ma
  • Publication number: 20170042959
    Abstract: Antimicrobial peptides represent a relatively new discovery in the immune system path-way. Recent designs of synthetically engineered antimicrobial peptides have demonstrated increased potency and efficacy/tolerability, enhanced specificity, and reduced toxicity in comparison. One such peptide, XYLENTRA, has showed significant promise from significant in vitro studies against a large number of pathogens through to extensive animal studies and is very solute resistant. These types of antimicrobial peptides show enormous promise in treating patients with chronic wounds or burn wound sepsis. The test compound Xylentra® showed significant antibacterial activity on test organisms Staphylococcus aureus MTCC 96 and Pseudomonas aeroginosa MTCC 741. A substantial decrease in the microbial population level was observed in animals treated with peptide using the protocol described in detail in the application.
    Type: Application
    Filed: August 11, 2015
    Publication date: February 16, 2017
    Inventor: Ram Isanaka
  • Publication number: 20170042960
    Abstract: The present invention provides compositions and methods for treating hepatitis B virus (HBV) infection as well as methods for identifying a compound or a composition that is suitable for treating HBV infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit HBV replication or treat HBV infection in a mammal. In particular, the present invention provides compositions and methods for treating hepatitis B infection by inhibiting interaction between HBV x protein and a Bcl-2 family protein or by reducing the expression level of a Bcl-2 family protein.
    Type: Application
    Filed: November 4, 2016
    Publication date: February 16, 2017
    Inventors: Ding Xue, Xin Geng
  • Publication number: 20170042961
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Application
    Filed: August 23, 2016
    Publication date: February 16, 2017
    Inventors: William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang, Weidong Zhong
  • Publication number: 20170042962
    Abstract: An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle hypoactivity), which has an improved NO production enhancing effect is provided. A NO production enhancer comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients. An agent for preventing or ameliorating vascular endothelial malfunction, comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients. An agent for preventing or ameliorating a symptom caused by vascular endothelial malfunction, comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Inventors: Masahiko Morita, Miho Komatsu, Takahiro Hara
  • Publication number: 20170042963
    Abstract: The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-?B which is overexpressed specifically in cancer stem cells present in tumors.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 16, 2017
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee, Jin Sook Suh
  • Publication number: 20170042964
    Abstract: The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a Nuclear Transport Modifier may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease in cholesterol and triglyceride levels in the blood and liver, a decrease in atherosclerotic lesion size, a decrease in body weight and in hyperglycemia, a reduction of fatty liver inflammation, and an improvement in liver function.
    Type: Application
    Filed: June 20, 2016
    Publication date: February 16, 2017
    Inventors: Jack J. Hawiger, Ruth Ann Veach, Jozef Zienkiewicz, Yan Liu, Robert D. Collins, Amy S. Major
  • Publication number: 20170042965
    Abstract: Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken.
    Type: Application
    Filed: August 18, 2016
    Publication date: February 16, 2017
    Inventors: Michael P. Bevilacqua, Diego Benitez, Jarrod A. Hanson
  • Publication number: 20170042966
    Abstract: Agents and formulations and cells including plant extracts are useful in a method for controlling pathogen infestation in human and animal subjects. A method for inhibiting growth or infestation of a pathogen in or on a human or animal subject, includes contacting the pathogen with an effective amount of a combination of a plant defensin or a functional natural or synthetic derivative or variant thereof and either: (i) a proteinase inhibitor; or (ii) a chemical pathogenicidic or pathogenostatic agent; in a combined amount effective to inhibit growth or infestation of the pathogen.
    Type: Application
    Filed: April 24, 2015
    Publication date: February 16, 2017
    Inventors: Nicole VAN DER WEERDEN, Marilyn Anne ANDERSON, Jennifer PAYNE
  • Publication number: 20170042967
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 16, 2017
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, Jr., Menno Van Lookeren, William I. Wood
  • Publication number: 20170042968
    Abstract: This application is drawn to a method of using an isoform NELL-1 peptide, and compositions thereof for bone formation or for treating, preventing, or ameliorating osteoporosis.
    Type: Application
    Filed: September 14, 2016
    Publication date: February 16, 2017
    Inventors: Kang Ting, Chia Soo
  • Publication number: 20170042969
    Abstract: The present invention relates to a pharmaceutical composition comprising a (poly)peptide which comprises or consists of QEP or a QEP derivative thereof a nucleic acid molecule encoding said (poly)peptide or a vector comprising said nucleic acid molecule, for use in the prevention or in the treatment of a disease or disorder caused by, physiologically linked to or associated with glucose and/or galactose uptake, wherein said pharmaceutical composition is to be administered under a high-sugar condition. Furthermore, the pharmaceutical composition of the invention is for use in increasing insulin sensitivity. The invention further relates to a food composition comprising said (poly)peptide. The invention further relates to a method of screening for and/or identifying a compound suitable to prevent or treat said disease or disorder under a high-sugar condition.
    Type: Application
    Filed: April 23, 2015
    Publication date: February 16, 2017
    Inventors: Alexandra FRIEDRICH, Jürgen GROLL, Hermann KOEPSELL, Maike VEYHL-WICHMANN
  • Publication number: 20170042970
    Abstract: Disclosed herein are methods for treating an angiogenesis-related condition or disease in a subject in need thereof. Said method includes administering to the subject a peptide having at least 90% sequence identity of the sequence of SEQ ID NO: 1 or SEQ ID NO:3 in a therapeutically effective amount.
    Type: Application
    Filed: April 29, 2015
    Publication date: February 16, 2017
    Applicants: MacKay Memorial Hospital, ASCLEPIUMM TAIWAN CO., LTD.
    Inventors: Chi-Sheng LU, Hung-I YEH, Min-Che CHEN, Chun-Wei CHEN
  • Publication number: 20170042971
    Abstract: The present invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid, said amino acid preferably having a net charge at a pH between about 6 and 8. The ingredients of the formulation preferably provide stability over repeated freeze-thaw cycles. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory disorders, preferably osteoarthritis.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Klaus Hellerbrand, Rainer Sigl
  • Publication number: 20170042972
    Abstract: The present invention is directed to methods and compositions for achieving drug-free remission in subjects with early RA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule until Disease Activity Score Calculator for Rheumatoid Arthritis (DAS)-defined remission is achieved and then withdrawing the RA therapy.
    Type: Application
    Filed: April 23, 2015
    Publication date: February 16, 2017
    Inventor: Chetan KARYEKAR
  • Publication number: 20170042973
    Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 16, 2017
    Inventors: Michael A. Rudnicki, Fabien Le Grand
  • Publication number: 20170042974
    Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.
    Type: Application
    Filed: October 31, 2016
    Publication date: February 16, 2017
    Inventors: Martin Joseph CUMMINS, Chau-Ting YEH, Ching-Yuan LEE
  • Publication number: 20170042975
    Abstract: The present invention relates to an isolated peptide for use in the treatment of cancer consisting of 12 to 50 amino acid residues comprising: at least two beta-strands, or at least two alpha-helices, or at least one beta-strand and at least one alpha-helix; wherein said beta-strands and/or alpha-helices are preferably separated from each other by at least one turn, wherein the peptide has a net positive charge of +7 or more; wherein said peptide comprises at least one peptide moiety having amino acid sequence (X1)M-X2-(X3)P-X4-(X5)Q-X6-(X7)S or the reverse sequence thereof, wherein X1 is a hydrophobic amino acid, preferably selected from the group consisting of phenylalanine (Phe), alanine (Ala), leucine (Leu) and valine (Val), X2 is a hydrophobic amino acid, preferably tryptophan (Trp), X3 is selected from the group consisting of alanine (Ala), arginine (Arg), glutamine (Gln), asparagine (Asn), proline (Pro), isoleucine (Ile), leucine (Leu) and valine (Val), X4 is selected from the group consisting of isole
    Type: Application
    Filed: October 5, 2016
    Publication date: February 16, 2017
    Inventors: Dagmar Zweytick, Karl Lohner, Sabrina Riedl
  • Publication number: 20170042976
    Abstract: Compositions of the invention include glycoproteins, such as transferrin, and metal-based coordination complexes, which are preferably chemotherapeutic compounds and more preferably tunable photodynamic compounds. The compositions are useful as in vivo diagnostic agents, and as therapeutic agents for treating or preventing diseases including those that involve hyperproliferating cells in their etiology, such as cancer. Compositions of the invention are further capable of destroying microbial cells, such as bacteria, fungi, and protozoa, and destroying viruses. Treatment methods of the invention can treat conditions throughout the body, including conditions located across the blood-brain barrier, the retina-blood barrier and the blood-cerebrospinal fluid barrier.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 16, 2017
    Inventor: Arkady MANDEL
  • Publication number: 20170042977
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.
    Type: Application
    Filed: March 22, 2016
    Publication date: February 16, 2017
    Inventors: Farah Natoli, Gaozhong Zhu, Jennifer Terew, Yuan Jiang, Jamie Tsung, Zahra Shahrokh, Brian Vernaglia, Jing Pan, Richard Pfeifer, Pericles Calias
  • Publication number: 20170042978
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Application
    Filed: February 4, 2016
    Publication date: February 16, 2017
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh